Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Viral Vector and Plasmid DNA Testing Services Market – Market Insights

Viral vectors are widely used in gene therapies. The viral vectors are majorly used by researchers to deliver genetic materials in the cells. Viral vectors are playing significant role in the pharmaceutical sector, as many research and innovations are ongoing for the development of drugs for treating cancer, cardiovascular diseases, ophthalmology, hematology, and many others.

Market players are focusing on partnership to expand their business in the viral vector and plasmid DNA testing services market, which is expected to boost growth of the market over the forecast period. For instance, in November 2019, Harvard University and Massachusetts Institute of Technology entered into a partnership with GE Healthcare Life Sciences, Fujifilm, and five research hospitals, in order to build a research center worth US$ 50 million at Greater Boston, U.S. for developing new cell and gene therapy. The hospitals involved in the partnership include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, the Dana-Farber Cancer Institute, and Massachusetts General Hospital.

The global viral vector and plasmid DNA testing services market was valued at US$ 76.4 million in 2018 and is expected to exhibit a CAGR of 25.0% over the forecast period (2019-2027).

Figure 1. Global Viral Vector and Plasmid DNA Testing Services Market Value (US$ Mn), by Region, 2018

Viral Vector and Plasmid DNA Testing Services  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Inorganic growth strategies such as business expansions adopted by key players is expected to boost growth of the global viral vector and plasmid DNA testing services market.

The global viral vector and plasmid DNA testing services market is expected to witness significant growth over the forecast period, owing to business expansions by key players. For instance, in May 2016, Eurofins MWG Operon LLC., a subsidary of Eurofins Scientific Company, announced to open a new DNA sequencing Lab in Toronto, Canada, in order to offer sequencing services using Sanger method to researchers in Canada.

Figure 2. Global Viral Vector and Plasmid DNA Testing Services Market Share (%), by Testing Services, 2019 and 2027

Viral Vector and Plasmid DNA Testing Services  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing acquisitions by key players for better penetration in the market is expected to drive the market growth.

North America is expected to hold a dominant position in the global viral vector and plasmid DNA testing services market, owing to increasing acquisition by key players, which is expected to drive the North America market growth over the forecast period. For instance, in September 2016, Charles River Laboratories, Inc. acquired Agilux Laboratories, Inc. for around US$ 62.0 million. The acquisition strengthened Charles River Laboratories, Inc.’s offering for client’s drug research process.

Moreover, Europe is expected to be the second dominating region in the global viral vector and plasmid DNA testing services market over the forecast period, owing to acquisitions by key players in the region. For instance, in 2017 Eurofins Scientific acquired Amatsigroup, a CDMO offering preclinical and clinical phase services for the development of human and veterinary drugs. The acquisition is expected to strengthen Eurofins position in its BioPharma services business.

Key Players

Major players operating in the global viral vector and plasmid DNA testing services market include Charles River Laboratories, Inc., WuXi AppTec Co., Ltd., Cobra Biologics and Pharmaceutical Services, Merck KGaA, Lonza, Eurofins Scientific, FinVector Vision Therapies, Advanced Bioscience Laboratories, Inc., Takara Bio Inc., ViruSure GmbH, and Genezen Laboratories among others.

Viral vectors are the best approach used in the gene therapies and therefore, testing services are the key factors for the timely development of viral vector-based therapies. Viral vector characterization plays an important role for orthogonal analytical approaches. The characterization is significant through the regulatory perspective, which include product safety, identity, purity, and potency. Nowadays, viral vector are the leading vehicle for the multiple virus-based drugs, which are approved in the global market and are developed for various treatments such as cancer and neurology, hematology, ophthalmology, and metabolic or muscular disorders. Viral-based products has the promising future in the pharmaceutical sector for many innovations.

The ongoing clinical trials on the viral vectors and plasmid DNA for various treatment is expected to fuel growth of the market in the forecast period. For instance, according to data published in the Journal of Gene Medicine, March 2018, till November 2017, around 2,600 gene therapy clinical trials were ongoing that are approved in 36 countries which include the U.S., the U.K., Australia, Canada, China, France, Germany, Japan, Switzerland, the Netherlands, and others. Moreover, diseases targeted by gene therapies include cardiovascular diseases, cancer, inflammatory and infectious diseases, Hemophilia A and B, severe combined immunodeficiency (SCID), ocular diseases, neurological diseases, and others.

Furthermore, favorable regulations imposed by the regulatory authorities for the specific utilization of viral vectors or plasmid DNA in the industries are expected to fuel growth of the market. For instance, in March 2018, the European Medicines Agency (EMA) drafted a guideline on the quality, non-clinical, and clinical aspects of gene therapy medicinal products, wherein the agency stated that characterization studies should be conducted throughout the development process right from starting materials, intermediates, drug substance and drug product in the gene therapy medicinal products (GTMP). The agency also stated that the characterization of the vector should include all components, but in particular, those present in the final product to be administered.

Market Dynamics

The viral vector and plasmid DNA testing services market is expected to witness significant growth over the forecast period, owing to rising number of business expansion by opening a new center or process development service (PDS). For instance, in February 2019, LakePharma, Inc., a contract research, development, and manufacturing organization (CRDMO), announced the availability of its vector center  commercially located at Worcester, U.S. for offering broad range of services such as viral vector production, CAR-T engineering, analytical development of vectors, and others. The company also made lentivirus, adeno-associated virus (AAV), and baculovirus production systems available at the center.

Moreover, acquisitions by the major players are expected to drive growth of viral vector and plasmid DNA testing services market over the forecast period. For instance, in November 2018, ABL Europe SAS, a subsidiary of ABL, Inc., acquired a former Accinov GMP manufacturing site located in Lyon, France for expansion of viral vector GMP contract manufacturing capacity in the gene therapy space. The site has 3 GMP suites, laboratory and office, which provides process development, and analytical support for gene therapy.

Key features of the study:

  • This report provides in-depth analysis of the viral vector and plasmid DNA testing services market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2019 -2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global viral vector and plasmid DNA testing services market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as part of this study include Charles River Laboratories, Inc., WuXi AppTec Co., Ltd., Cobra Biologics and Pharmaceutical Services, Merck KGaA, Lonza, Eurofins Scientific, FinVector Vision Therapies, Advanced Bioscience Laboratories, Inc., Takara Bio Inc., ViruSure GmbH, and Genezen Laboratories amongst others
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology upgradation, market expansion, and marketing tactics
  • The global viral vector and plasmid DNA testing services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the viral vector and plasmid DNA testing services market

Detailed Segmentation:

  • Global viral vector and plasmid DNA testing services market, by testing services:
    • Safety
    • Genetic Characterization
    • Purity
    • Identity
    • Potency
  • Global viral vector and plasmid DNA testing services market, By end user:
    • Research Organizations
    • Pharmaceutical and Biotechnological Companies
  • Global viral vector and plasmid DNA testing services market, By Region:
    • North America
      • By Testing Services:
        • Safety
        • Genetic Characterization
        • Purity
        • Identity
        • Potency
      • By End User:
        • Research Organizations
        • Pharmaceutical and Biotechnological Companies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Testing Services:
        • Safety
        • Genetic Characterization
        • Purity
        • Identity
        • Potency
      • By End User:
        • Research Organizations
        • Pharmaceutical and Biotechnological Companies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Testing Services:
        • Safety
        • Genetic Characterization
        • Purity
        • Identity
        • Potency
      • By End User:
        • Research Organizations
        • Pharmaceutical and Biotechnological Companies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Testing Services:
        • Safety
        • Genetic Characterization
        • Purity
        • Identity
        • Potency
      • By End User:
        • Research Organizations
        • Pharmaceutical and Biotechnological Companies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Pakistan
        • Rest of Asia Pacific
    • Middle East
      • By Testing Services:
        • Safety
        • Genetic Characterization
        • Purity
        • Identity
        • Potency
      • By End User:
        • Research Organizations
        • Pharmaceutical and Biotechnological Companies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Testing Services:
        • Safety
        • Genetic Characterization
        • Purity
        • Identity
        • Potency
      • By End User:
        • Research Organizations
        • Pharmaceutical and Biotechnological Companies
      • By Country/Region:
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • Charles River Laboratories, Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • WuXi AppTec Co., Ltd.
    • Cobra Biologics and Pharmaceutical Services
    • Merck KGaA
    • Lonza
    • Eurofins Scientific
    • FinVector Vision Therapies
    • Advanced Bioscience Laboratories, Inc.
    • Takara Bio Inc.
    • ViruSure GmbH
    • Genezen Laboratories

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Testing Services
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Guidelines
    • Regulatory Scenario
    • Merger & Acquisitions
    • Product Launch
    • Epidemiology
    • Pipeline Analysis
    • New Product Launches
    • List of Approved Products
    • Pest Analysis
  4. Global Viral Vector and Plasmid DNA Testing Services Market, By Testing Services, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Safety
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Genetic Characterization
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Purity
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Identity
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Potency
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Global Viral Vector and Plasmid DNA Testing Services Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Research Organizations
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Pharmaceutical and Biotechnological Companies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Viral Vector and Plasmid DNA Testing Services Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Testing Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Testing Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Testing Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Testing Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Pakistan
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Testing Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Testing Services, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Charles River Laboratories, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • WuXi AppTec Co., Ltd.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Cobra Biologics and Pharmaceutical Services
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Merck KGaA
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Lonza
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Eurofins Scientific
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • FinVector Vision Therapies
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Advanced Bioscience Laboratories, Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Takara Bio Inc.
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • ViruSure GmbH
        • Company Highlights
        • Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Genezen Laboratories
        •  Products Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 26 market data tables and 22 figures on "Viral Vector and Plasmid DNA Testing Services Market - Global forecast to 2027”.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner